logo/base Created with Sketch.

FibroScan® Compact 530

The portable non-invasive solution for efficient liver disease management

Powered by LSM by VCTE™ and CAP™ for liver fibrosis and liver steatosis assessment.


From cart-based to transportable

With its optional roll stand, 15” interactive touchscreen display and durable ergonomic design, FibroScan® Compact 530 is the perfect liver assessment solution for any point-of-care setting.

Smartly adaptable to all settings

FibroScan® Compact 530 is easy to handle and transport (10 kg). It is a battery-powered device and is provided with transport case.

As an option, the dedicated roll stand provides a lockable drawer for probes, and a hard washable keyboard.

FibroScan® Compact 530 is adapted to all patient morphologies as it can be used with all probes S+, M+ and XL+. The two probe connectors allows to easily switch between probes during exam.

LSM by VCTE™ is unique, patented and validated for liver fibrosis assessment. It is the standard for non-invasive evaluation of liver stiffness1 with 3,800 international peer-reviewed publications.

CAP™ is unique patented and validated for liver steatosis assessment2,3  with 1,130 international peer-reviewed publications.

What our users say


As a clinical researcher, I rely heavily on FibroScan® to select the right patient for the right study. Clinical trials in non-alcoholic steatohepatitis typically include patients with specific fibrosis stages. It is thus important to have reliable fibrosis assessment and avoid unnecessary liver biopsies.

Vincent Wong | Hepatologist from Hong Kong

chevron chevron

FibroScan® Compact 530 comes with a dedicated support

From installation, to training and local support, we provide you with the highest quality of services.

1.European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.
2.Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022.
3.Recio E, Cifuentes C, Macías J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool or the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25(8):905-911.doi:10.1097/MEG.0b013e32835f4c3d.

Products in the FibroScan® range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). These devices are designed for use in a medical practice in order to measure liver stiffness and ultrasound attenuation in patients with liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies.